Xin Yao

机构：Tianjin Medical University Cancer Institute and Hospital, Jianghan University, National Clinical Research Center for Digestive Diseases, Nanjing Medical University · ORCID：0000-0003-1569-8096

发表论文 53 篇 · 总被引 1050 次 · h-index 14

代表论文

• Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (2020 · Clinical Cancer Research · 被引 289)
• Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials (2023 · Journal of Clinical Oncology · 被引 177)
• Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 (2021 · Clinical Cancer Research · 被引 70)
• RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. (2022 · Journal of Clinical Oncology · 被引 33)
• Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial (2022 · BMC Medicine · 被引 23)
• MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes (2025 · Redox Biology · 被引 14)